Autophagy represses hepatic carcinogenesis

Juliette Paillet; Guido Kroemer

doi:10.1080/23723556.2019.1573080

Autophagy represses hepatic carcinogenesis

Mol Cell Oncol. 2019 May 13;6(4):1573080. doi: 10.1080/23723556.2019.1573080. eCollection 2019.

Authors

Juliette Paillet^{1

2

3

4

5

6}, Guido Kroemer^{1

2

3

4

5

7

8

9}

Affiliations

¹ Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
² Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus, Villejuif, France.
³ INSERM, Paris, France.
⁴ Université Paris Descartes, Paris, France.
⁵ Université Pierre et Marie Curie, Paris, France.
⁶ Faculty of Medicine, Paris Sud/Paris XI University, Le Kremlin-Bicêtre, France.
⁷ Center of Systems Medicine, Chinese Academy of Science, Suzhou, China.
⁸ Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.
⁹ Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

Abstract

Hepatocyte-specific knockout of the essential autophagy gene Autophagy-related 7 (Atg7) is sufficient to cause hepatic carcinogenesis. A recent paper by Lee et al. unveils the molecular pathway accounting for hepatic hypertrophy and hyperplasia followed by malignant transformation. This pathway involves the overactivation of the transcription factor yes-associated protein (YAP), which turns out to be an autophagic substrate. Of note, the transcriptional signature activated in mouse hepatocytes lacking Atg7 resembles that found in non-alcoholic steatohepatitis (NASH), as well as in the steatohepatitic subtype of human hepatocellular carcinomas.

Keywords: Age-related disease; NK cells; cytotoxic T cells; immunosenescence; senescence.

Publication types

Review

Grants and funding

GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Inserm Transfert; Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM).